David Cole
Head of Research Accession Therapeutics
Dave is a recognised expert in immuno-oncology with over 20 years’ experience, including research leading to the discovery and validation of novel drug candidates plus development of collaborations with academia and industry. In his academic career Dave worked as a principal investigator and Wellcome Trust Fellow at Cardiff University, studying the nature of T cell antigen recognition, after he received his D.Phil in Molecular Immunology from the University of Oxford
Seminars
Monday 8th June 2026
Chair’s Opening Remarks
8:50 am
Monday 8th June 2026
Chair’s Closing Remarks
6:00 pm
Thursday 9th July 2026
Addressing Solid Tumour Heterogeneity: TROCEPT-Mediated Activation of a Universal Bispecific T-cell Engager via IV Delivery
9:00 am
- Targeting tumour heterogeneity by focusing on markers expressed across all cancer cells, ensuring no malignant cell is missed
- Overcoming immune suppression with therapies potent enough to activate immune responses despite the tumour’s inhibitory environment
- Reducing off-target toxicity by restricting therapeutic activity to tumour cells, expanding the therapeutic window for safer treatment
